Manager TitleAgeSince
Chief Operating Officer - 14/11/2022
Director TitleAgeSince
Director/Board Member 61 16/08/2005
Chairman 67 19/09/2014
Director/Board Member 55 05/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 1.28M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-8.56%+22.91%+58.73% 53.6B
+2.80%+3.03%-14.71%-12.00% 22.91B
-1.05%-7.19%-12.62%+338.85% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-3.25%+30.55%-29.84% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+2.82%-3.51%+46.29%+159.39% 13.33B
Average -1.40%-1.88%+37.88%+163.01% 25.98B
Weighted average by Cap. +0.12%-1.70%+30.92%+121.40%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14